03320 CHINARES PHARMA
- 5.040
- +0.080+1.61%
CHINARES PHARMA News
China Resources Pharmaceutical (03320.HK): Donga Ejiao's net profit of 353 million yuan in the first quarter increased 53.43% year-on-year
Gelonghui, April 26 | China Resources Pharmaceutical (03320.HK) announced that Donga Ejiao (000423.SZ)'s revenue for the first quarter of 2024 was 1,453 billion yuan, up 35.95% year on year; net profit attributable to shareholders of listed companies (Donga Ejiao) was 353 million yuan, up 53.43% year on year; net profit attributable to shareholders of listed companies (Donga Ejiao) after deducting non-recurring profit and loss was 329 million yuan, up 54.79% year on year; basic earnings per share were 0.5488 yuan.
華潤醫藥：公告東阿阿膠截至2024年3月31日止三個月的未經審核財務業績
華潤醫藥：公告華潤雙鶴截至2024年3月31日止三個月的未經審核財務業績
華潤醫藥：2023年年報
SDIC Securities: The industry is heavily state-owned capital, and the trend of mergers and acquisitions of pharmaceutical distribution companies is expected to accelerate further in 24 years
The new round of state-owned enterprise reform also emphasizes specialized integration in the medical and health sector. The pharmaceutical distribution industry is heavily state-owned and driven by superposition policies. At the time point of 2024, the trend of mergers and acquisitions of domestic pharmaceutical distribution companies is expected to further accelerate.
China Resources Pharmaceuticals (03320.HK): Zheng Guiyu Appointed as Secretary and Authorized Representative
Gelonghui, April 24, 丨 China Resources Pharmaceutical (03320.HK) announced that Su Yaofeng has resigned as company secretary since April 24, 2024 and will no longer act as an authorized representative of the company as stipulated in the Hong Kong Stock Exchange Limited securities listing rules. The board of directors is pleased to announce that Zheng Guiyu has been appointed as company secretary and authorized representative with effect from April 24, 2024.
China Resources Pharmaceutical (03320): China Resources Liberal Arts Biotech's net profit for the first quarter of 152.2 million yuan decreased by 12.97% year-on-year
China Resources Pharmaceuticals (03320) announced that China Resources Biotech, a subsidiary of the company, will be 3 as of March 31, 2024...
華潤醫藥：公告華潤博雅生物截至2024年3月31日止三個月的未經審核財務業績
China Resources Pharmaceuticals (03320.HK): China Resources's net profit to mother was 1,364 billion yuan in the first quarter, up 18.49% year-on-year
Gelonghui, April 22丨China Resources Pharmaceutical (03320.HK) announced that China Resources 39 (000999.SZ) achieved operating income of 7.294 billion yuan in the first quarter of 2024, up 14.82% year on year; net profit attributable to shareholders of China Resources 39 billion yuan, up 18.49% year on year; net profit attributable to China Resources 39 shareholders after deducting non-recurring profit and loss was 1,328 billion yuan, up 17.38% year on year; basic earnings per share were 1.39 yuan.
華潤醫藥：公告華潤三九截至2024年3月31日止三個月的未經審核財務業績
華潤醫藥：公告昆藥集團截止2024年3月31日止三個月的未經審核財務業績
China Resources Pharmaceutical (03320): Beijing Pharmaceutical has completed a transaction to transfer 100% of China Resources Zizhu's interests to China Resources Shuanghe
China Resources Pharmaceutical (03320) issued an announcement to register share transfers with relevant counterpart departments of the State Administration of Market Supervision and Administration...
China Resources Pharmaceuticals (03320.HK) completed the proposed internal restructuring involving China Resources Zizhu
Gelonghui, April 18, 丨 China Resources Pharmaceutical (03320.HK) announced the proposed internal restructuring of China Resources Zizhu Pharmaceutical Co., Ltd. (“China Resources Zizhu”). The board of directors is pleased to announce that the share transfer registration with the relevant counterpart department of the State Administration of Market Supervision and Administration has been completed. Therefore, as of the announcement date, according to the terms of the share transfer agreement, Beijing Pharmaceutical has completed a transaction to transfer 100% of China Resources Zizhu's interests to China Resources Shuanghe.
China Resources Pharma Unit Issues 3 Billion Yuan Bonds
China Resources Pharmaceutical Group (HKG:3320) said its unit CR Pharmaceutical Commercial sold 3 billion yuan of bonds in China, according to a Wednesday filing with the Hong Kong Exchange. Two varie
China Resources Pharmaceuticals (03320): China Resources Pharmaceuticals commercially issues no more than 3 billion yuan of corporate bonds
Zhitong Finance App News, China Resources Pharmaceutical (03320) announced that China Resources Pharmaceutical has issued the first issue of 2024 corporate bonds in China, with an issuance scale of no more than RMB 3 billion. The coupon interest rate for corporate bond type 1 is 2.45%, and the term is three years. The coupon interest rate for corporate bond type 2 is 2.63%, and the term is five years. The funds raised from the issuance of this issue of bonds will mainly be used to repay interest-bearing debts.
China Resources Pharmaceuticals (03320.HK) signs 2024 IT service procurement agreement with China Resources Mathematics
Gelonghui, April 12, 丨 China Resources Pharmaceutical (03320.HK) announced that on April 12, 2024, the company signed a 2024 IT service procurement framework agreement with China Resources Mathematics. According to this, the Group has agreed to purchase IT services from China Resources Mathematical Group for the period from April 12, 2024 to December 31, 2024.
China Resources Pharmaceutical (03320.HK): Donga Ejiao's net profit for the first quarter is expected to be about 334 million to 357 million yuan
Gelonghui, April 12, 丨 China Resources Pharmaceutical (03320.HK) issued an announcement. On April 11, 2024, Donga Ejiao (000423.SZ) announced its results forecast for the three months ending March 31, 2024. According to this, the net profit attributable to shareholders of Donga Ejiao for the three months ending March 31, 2024 is estimated to be approximately RMB 334 million to RMB 357 million (approximately RMB 2303 million for the same period last year). Net profit after deducting non-recurring profit and loss is estimated to be approximately RMB 309 million to RMB 332 million ( Approximately RMB 2 for the same period last year.
CHINARES PHARMA: ANNOUNCEMENT RESULTS ESTIMATE OF DONG-E-E-JIAO FOR THE THREE MONTHS ENDED 31 MARCH 2024
[Broker Focus] Tianfeng Securities maintains China Resources Pharmaceuticals (03320) “buy” rating, indicating rapid growth in the pharmaceutical business
Jinwu Financial News | According to Tianfeng Securities Research Report, China Resources Pharmaceutical (03320) issued the 2023 annual results announcement. In 2023, the company achieved operating income of 244.704 billion yuan, an increase of 12.2%; achieved gross profit of 38.337 billion yuan, an increase of 14.0%; realized net profit attributable to mother of 3.854 billion yuan, an increase of 10.1% year on year; realized net profit deducted from mother of 4.190 billion yuan, an increase of 21.7% year on year. The business growth of each division of the company was steady, and the pharmaceutical business performed well. According to the bank, as a leading comprehensive pharmaceutical leader in China, the bank believes that it is 2023
Haitong International: Maintaining China Resources Pharmaceutical's (03320) “Better Than Market” Rating Target Price of HK$8.12
The Zhitong Finance App learned that Haitong International released a research report stating that it maintains China Resources Pharmaceuticals (03320)'s “superior to the market” rating, with a target price of HK$8.12. It is estimated that 2024-26 will achieve revenue of 2710/2993/329.8 billion yuan, with corresponding growth rates of 10.8%/10.4%/10.2%, respectively; net profit to mother of 42.87/47.49/ 5.241 billion yuan, respectively, with corresponding growth rates of 11.2%/10.8%/10.4%, respectively. The bank believes that the Group will actively expand its business layout through epitaxial mergers and acquisitions, while continuing to integrate
Analysis
Price Target
No Data
